TN2009000102A1 - Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses - Google Patents

Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Info

Publication number
TN2009000102A1
TN2009000102A1 TN2009000102A TN2009000102A TN2009000102A1 TN 2009000102 A1 TN2009000102 A1 TN 2009000102A1 TN 2009000102 A TN2009000102 A TN 2009000102A TN 2009000102 A TN2009000102 A TN 2009000102A TN 2009000102 A1 TN2009000102 A1 TN 2009000102A1
Authority
TN
Tunisia
Prior art keywords
antibodies
tumor
resistant
generating active
resistance
Prior art date
Application number
TN2009000102A
Other languages
English (en)
French (fr)
Inventor
Liliane Goetsch
Alexendra Jouhanneaud
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of TN2009000102A1 publication Critical patent/TN2009000102A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TN2009000102A 2006-09-28 2009-03-26 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses TN2009000102A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0608514A FR2906533B1 (fr) 2006-09-28 2006-09-28 Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations
PCT/EP2007/060243 WO2008046724A1 (en) 2006-09-28 2007-09-27 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Publications (1)

Publication Number Publication Date
TN2009000102A1 true TN2009000102A1 (en) 2010-08-19

Family

ID=38164542

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000102A TN2009000102A1 (en) 2006-09-28 2009-03-26 Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses

Country Status (21)

Country Link
US (2) US8241646B2 (enExample)
EP (4) EP2081592B1 (enExample)
JP (1) JP5774276B2 (enExample)
KR (1) KR101504770B1 (enExample)
CN (1) CN101516394B (enExample)
AR (1) AR063061A1 (enExample)
AU (1) AU2007312437C1 (enExample)
BR (1) BRPI0717246A2 (enExample)
CA (1) CA2663561A1 (enExample)
FR (1) FR2906533B1 (enExample)
IL (1) IL197790A (enExample)
MA (1) MA30954B1 (enExample)
MX (1) MX2009003245A (enExample)
NO (1) NO20091613L (enExample)
NZ (1) NZ576420A (enExample)
RU (1) RU2515904C2 (enExample)
TN (1) TN2009000102A1 (enExample)
TW (1) TWI516276B (enExample)
UA (1) UA102812C2 (enExample)
WO (1) WO2008046724A1 (enExample)
ZA (1) ZA200902697B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CU23736A1 (es) * 2009-05-04 2011-11-15 Centro Inmunologia Molecular Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso
WO2011004899A1 (en) * 2009-07-06 2011-01-13 Takeda Pharmaceutical Company Limited Cancerous disease modifying antibodies
WO2011066417A2 (en) * 2009-11-24 2011-06-03 Carnegie Mellon University Antibodies and conjugates for modulators of angiogenesis
US8637027B2 (en) 2010-11-03 2014-01-28 Argen-X B.V. Anti c-Met antibodies
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
TW201613615A (en) 2014-06-30 2016-04-16 Academia Sinica Antagonists for interleukin-17 receptor B (IL-17RB) and its ligand IL-17B for cancer therapy
EP3197915A4 (en) 2014-09-22 2018-12-19 Intrinsic Lifesciences LLC Humanized anti-hepcidin antibodies and uses thereof
TWI740824B (zh) * 2015-04-27 2021-10-01 法商皮爾法伯製藥公司 新穎的ｉｇｆ－１ｒ抗體及其用於癌症診斷之用途（一）
TWI716400B (zh) * 2015-04-27 2021-01-21 法商皮爾法伯製藥公司 新穎的igf-1r抗體及其用於癌症診斷之用途（二）
CN108290936B (zh) * 2015-08-14 2022-07-12 默沙东公司 抗tigit抗体
RU2722451C1 (ru) * 2015-09-29 2020-06-01 Шанхай Чжанцзян Биотекнолоджи Ко., Лтд. Pd-1 антитела и их применение.
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct
WO2025111382A2 (en) * 2023-11-21 2025-05-30 Board Of Regents, The University Of Texas System Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6261596A (ja) * 1985-09-11 1987-03-18 Japan Found Cancer Res 薬剤耐性癌に関するモノクロ−ナル抗体およびその製造
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
ATE142879T1 (de) * 1992-02-06 1996-10-15 Merrell Pharma Inc Aufhebung von multi-drug-resistenz durch tetraarylethylene
IT1257893B (it) * 1992-06-17 1996-02-16 Ist Superiore Sanita Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5503984A (en) * 1993-04-13 1996-04-02 Health Research, Inc. Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein
US6245898B1 (en) * 1998-06-15 2001-06-12 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
AU2003216748B2 (en) 2002-01-18 2009-07-16 Pierre Fabre Medicament Novel anti-IGF-IR antibodies and uses thereof
US20040121965A1 (en) 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
MXPA06003886A (es) * 2003-10-08 2006-08-11 Ebioscience Reactivos de enlace de inmunoglobulina naturales y metodos de fabricacion y uso de los mismos.
ATE397924T1 (de) 2004-02-18 2008-07-15 Gpc Biotech Ag Satraplatin zur behandlung von resistenten oder refrkatären tumoren
EP1742060A1 (en) * 2005-01-24 2007-01-10 DIGILAB BioVisioN GmbH TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders.

Also Published As

Publication number Publication date
US20100146650A1 (en) 2010-06-10
EP2494984A1 (en) 2012-09-05
CA2663561A1 (en) 2008-04-24
EP2081592B1 (en) 2016-01-13
FR2906533B1 (fr) 2013-02-22
AU2007312437A1 (en) 2008-04-24
EP2081592A1 (en) 2009-07-29
NZ576420A (en) 2012-05-25
US8241646B2 (en) 2012-08-14
MA30954B1 (fr) 2009-12-01
TW200822934A (en) 2008-06-01
EP2491945B1 (en) 2016-12-07
CN101516394B (zh) 2014-07-30
IL197790A (en) 2016-10-31
EP2494984B1 (en) 2017-01-04
ZA200902697B (en) 2010-04-28
RU2009114682A (ru) 2010-11-20
CN101516394A (zh) 2009-08-26
US20130028835A1 (en) 2013-01-31
AU2007312437B2 (en) 2014-01-23
AU2007312437C1 (en) 2014-04-10
EP2497491A1 (en) 2012-09-12
EP2491945B9 (en) 2017-03-08
FR2906533A1 (fr) 2008-04-04
IL197790A0 (en) 2011-08-01
MX2009003245A (es) 2009-07-07
JP2010504743A (ja) 2010-02-18
KR20090057469A (ko) 2009-06-05
UA102812C2 (ru) 2013-08-27
WO2008046724A1 (en) 2008-04-24
AR063061A1 (es) 2008-12-23
EP2497491B1 (en) 2017-03-01
HK1131063A1 (en) 2010-01-15
NO20091613L (no) 2009-06-26
US8808667B2 (en) 2014-08-19
EP2491945A1 (en) 2012-08-29
RU2515904C2 (ru) 2014-05-20
TWI516276B (zh) 2016-01-11
KR101504770B1 (ko) 2015-03-20
BRPI0717246A2 (pt) 2013-10-08
JP5774276B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
TN2009000102A1 (en) Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses
PH12020550741A1 (en) Anti-cd79b antibodies and immunoconjugates and methods of use
UA106586C2 (uk) Анти-cd79b антитіла, і імунокон'югати та способи їх застосування
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
NZ598791A (en) Anti-gcc antibody molecules and related compositions and methods
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
SG170080A1 (en) Human monoclonal antibodies to o8e
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
WO2008067283A3 (en) Ovr110 antibody compositions and methods of use
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
MX2009005189A (es) Anticuerpos humanos monoclonales para btla y metodos de uso.
WO2009140177A3 (en) Anti-fn14 antibodies and uses thereof
MY161200A (en) Human cytomegalovirus neutralising antibodies and use thereof
EP1996716A4 (en) MANIPULATED ANTI-PROSTATE STEAM CELL RESPONSIVES (PSCA) ANTIBODIES FOR CANCER TARGETING
MX2011012060A (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-miloide.
WO2007126799A3 (en) Compositions and methods of use for antibodies of c-met
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
NZ606195A (en) Methods and compositions for liver cancer therapy
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
MX2010001237A (es) Nuevos anticuerpos.
NZ595863A (en) Antibodies to egfl7 and methods for their use